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infusion being least preferred (worst option in 45% of the cases). The second most 
relevant attribute was “necessity of combination therapy with methotrexate”, 
with DMARDs not requiring such combination being most preferred (in 43% of the 
cases). ConClusions: Our data indicate that, of the included attributes, the most 
important ones are route of administration (oral being the number one choice by 
majority) and combination therapy with methotrexate (with DMARDs not requiring 
such combination being the most preferred) for RA patients’ choice. This research 
was funded by Pfizer GmbH.
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objeCtives: Discrete-choice experiments are increasingly used to assess pref-
erences in health care. To date, very little is known about the transferability of 
patients’ preferences between jurisdictions. In this study, we aim to evaluate the 
preferences of patients with, or at risk of, osteoporosis for medication attributes 
in six European countries, and to assess whether preferences are transferable 
across these countries Methods: A discrete-choice experiment was conducted 
using a questionnaire in Belgium, France, Ireland, Spain, Switzerland and United 
Kingdom. Patients were asked to choose between two hypothetical unlabelled 
drug treatments (and an opt-out option) that vary in several attributes: efficacy 
in reducing the risk of fracture, type of potential common side-effects, mode 
and frequency of administration and out-of-pocket costs (only in countries with 
patients´ contribution on the cost of treatment). An efficient design was used to 
construct the treatment option choice sets and a mixed logit model was used to 
estimate patients’ preferences. Results: A total of 1,124 patients completed the 
experiment, with at least 100 patients per country. As expected, in all countries, 
patients preferred treatment with higher effectiveness and lower cost was pre-
ferred in the three countries in which a cost-attribute was part of the experiment. 
In all countries, patients preferred 6-monthly subcutaneous injection over weekly 
oral tablets. In most countries, patients also preferred monthly oral tablet and 
yearly intravenous injections over weekly oral tablets. Patients disliked being at 
risk of gastro-intestinal disorders more than being at risk of skin reactions and 
flu-like symptoms, except in Spain. There were significant differences between 
countries for some levels of attributes. ConClusions: This study suggests that 
the preferences of patients for osteoporotic drug therapy did not substantially 
differ between six European countries. However, for levels of some attributes, 
significant differences were observed.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in axial spondyloarthritis (axSpA), 
including ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), 
over 96 weeks (wks) of the RAPID-axSpA trial. Methods: The RAPID-axSpA trial 
(NCT01087762) is double-blind and placebo-controlled to Wk24, dose-blind to 
Wk48, and open-label to Wk204. Patients fulfilled ASAS criteria and had active 
axSpA. Patients originally randomized to CZP (200mg Q2W or 400mg Q4W, fol-
lowing 400mg loading dose at Wks 0, 2, 4) continued on their assigned dose in 
the dose-blind phase and OLE. Here we report PRO data for the CZP-treated rand-
omized set, including mean change from baseline and the proportion of patients 
achieving a Minimal Clinically Important Difference (MCID). Missing data were 
imputed by LOCF. Correlations between clinical and patient-reported outcomes 
were also investigated. Results: Of 218 patients randomized to CZP, 203 (93%) 
completed Wk24, 191 (88%) Wk48, and 174 (80%) Wk96. Rapid improvements from 
baseline to Wk24 were maintained to Wk96 in all patient subpopulations (overall 
axSpA, AS, nr-axSpA) in pain (Wk24: -3.2, -3.2, -3.3; Wk96: -3.6, -3.6, -3.7); fatigue 
(Wk24: -2.7, -2.5, -2.9; Wk96: -2.9, -2.8, -3.1); BASFI (Wk24: -2.4, -2.3, -2.4; Wk96: 
-2.6, -2.6, -2.6); ASQoL (Wk24: -5.1, -4.8, -5.5; Wk96: -5.7, -5.5, -6.1) and sleep (Wk24: 
-12.8, -10.5, -15.7; Wk96: -13.9, -11.6, -16.7). CZP-treated patients also maintained 
improvements in SF-36 components and domains. Sustained improvements in 
the proportion of patients (overall axSpA, AS, nr-axSpA) achieving MCID (%) were 
observed in fatigue (Wk24: 78.4, 76.0, 81.4; Wk96: 67.0, 70.2, 62.9); BASFI (Wk24: 
67.4, 68.6, 66.0; Wk96: 64.2, 68.6, 58.8) and ASQoL (Wk24: 69.3, 71.1, 67.0; Wk96: 65.6, 
66.9, 63.9). Similar outcomes were seen with both dosing regimens. Correlations 
were observed between improvements in PROs (pain/fatigue/SF-36) and clinical 
outcomes (ASDAS) (data not shown). ConClusions: Improvements in PROs 
(including pain, fatigue and ASQoL) were maintained over 96 wks in both the 
AS and nr-axSpA subpopulations. Sustained improvements in the proportion of 
patients achieving MCID were also reported.
95% CI: 0.53-2.07) and psoriasis (OR: 1.07; 95% CI: 0.56-2.03). ConClusions: More 
than half of the PsA patients were persistent with the index subcutaneous biologic 
over a 12-month period with similar persistence rates observed among those with 
and without psoriasis and DMARD use.
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objeCtives: To assess medication adherence to DMARD in patients with 
Rheumatoid Arthritis using CQR and MARS tools, identification of factors affecting 
adherence and its effect on quality of life. Methods: A randomly selected sample 
of 110 adult patients with RA on DMARDs admitted to hospital were asked about 
their medication adherence, through self-report questionnaire [CQR and MARS] and 
quality of life was assessed by HAQ (Health Assessment Questionnaire). Additionally, 
various factors affecting adherence were identified. Results: According to the tools 
used, 86.4% (CQR), 74.29% (MARS -mean cut point) and 95.45% (MARS -prior study 
cut point) of patients showed adherence towards DMARD. Better adherence was 
seen in patients with primary education (COR- 94%) or secondary education (MARS 
-83%). Patients who suffered from RA for more than 2yrs showed better adherence 
(CQR- 93%) compared to those with recent disease (< 2yrs) (CQR- 89%). Non adher-
ence was seen in patients having co-morbidities compared to patients with only RA 
(CQR- 91% vs 94%; MARS- 62% vs 82%). Mean HAQ of adherent patients was better 
(2.83±1.05) than non-adherent patients (3.23 ± 0.74). Adherent patients showed mod-
erately active disease state (Mean DAS – 5.96 ± 1.67) whereas, non-adherent patients 
showed highly active disease state (Mean DAS – 6.70 ± 0.84). ConClusions: Patient 
reported questionnaires showed disease duration of less of 2yrs, and patients with 
co-morbidities lead to Non-adherence which worsened disease activity which lead 
to decreased quality of life.
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objeCtives: Psoriatic arthritis (PsA) is a multi-factorial disease that affects the skin, 
joints and soft tissues. Two of the commonly used measures for PsA are the Psoriasis 
Area and Severity Index (PASI, 0-100 scale) and the Health Assessment Questionnaire 
(HAQ, 0-3 scale) for skin and joints symptoms, respectively. Previous work in the 
area has estimated a relationship between these patient-reported instruments and 
utility (SF-36 mapped to the EQ-5D). The objectives of this study were to calculate 
patient-reported utility and investigate the consistency of the relationship between 
PASI, HAQ and utility with previously published estimates, based on the PSUMMIT 
trials of ustekinumab versus placebo. Methods: Patient level data from PSUMMIT1 
(anti-TNFα naïve) and PSUMMIT2 (both anti-TNFα naïve and experienced) were 
analysed in Stata 11. SF-36 data were converted to EQ-5D using the mapping by 
Rowen et al., with regression analysis used to estimate the relationship between 
PASI, HAQ and the resulting utility (including multiplicative terms). Goodness of fit 
was determined by the adjusted R2 and Root Mean Squared Error (RMSE). Results: 
Anti-TNFα naïve and experienced patients had a baseline utility of 0.50 and 0.48, 
respectively. Utility improved over the 24-week blinded period by 0.04/0.06 in the 
placebo arms for anti-TNFα naïve and experienced, and 0.11/0.13 in the treatment 
arms. In regression analysis utility was predicted as 0.897 – 0.004xPASI - 0.298xHAQ 
(adjusted R2 0.60, RMSE 0.12), similar to previously published estimates. Adding a 
multiplicative term for PASI and HAQ did not improve goodness of fit statistics, 
although baseline methotrexate use was linked to a lower utility. ConClusions: 
Patients with PsA have a low level of health-related quality of life that improves with 
treatment. The determinants of utility in the PSUMMIT trials were the skin and joint 
symptoms faced by patients, in keeping with previous estimates.
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objeCtives: There is a variety of biologic and non-biologic disease modifying anti-
rheumatic drugs (DMARDs) available for the treatment of rheumatoid arthritis (RA). 
These DMARDs are associated with different characteristics in key attributes such as 
mode of administration, side effects, etc. The current study assessed the importance 
of treatment characteristics for RA patients’ preferences. Methods: In a discrete 
choice experiment (DCE), 1570 RA patients are asked to choose the most and the 
least preferred DMARD (best-worst-scaling) among hypothetical multi-attribute 
treatment alternatives with varying levels of key attributes, as defined in focus 
groups: mode of administration, frequency of administration, time till onset of 
drug effect, necessity of combination therapy with methotrexate, and side effects. 
The multi-profile case design simulates a real choice situation between different 
hypothetical treatment alternatives. Interim analysis was conducted after half the 
sample size had been reached. Results: Interim analysis included 836 patients 
from 33 office based rheumatologists across Germany. Majority of patients were 
female (74%), 50 to 64 years of age (46%), with < 10 years of disease duration (54%), 
and reported experience with injectable DMARDs (63%). Mode of administration 
appeared the most important attribute guiding patients’ preferences, with ‘oral 
application’ being most desired (selected as best option in 51% of the cases) and 
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randomized to CZP at Wk0, 91% completed Wk24, 87% Wk48, and 80% Wk96. Rapid 
improvements observed to Wk24 were maintained to Wk96 for pain (Wk24 and 
Wk96; CFB: -28.5 and -31.3; MCID: 69.2% and 66.3%), fatigue (Wk24 and Wk96; CFB: 
-2.0 and -2.4; MCID: 64.1% and 60.4%), HAQ-DI (Wk24 and Wk96; CFB: -0.48 and 
-0.52; MCID: 48.7% and 48.0%), SF-36 PCS (Wk24 and Wk96; CFB: 8.01 and 9.01; MCID: 
67.4% and 60.1%), SF-36 MCS (Wk24 and Wk96; CFB: 4.50 and 3.92; MCID: 50.9% and 
43.6%), PsAQoL (Wk24 and Wk96; CFB: -3.87 and -4.50), and DLQI (Wk24 and Wk96; 
CFB: -5.8 and -6.0; MCID: 40.7% and 41.0%). Similar improvements were observed 
with both dosing regimens and in patients with or without prior anti-TNF exposure. 
Correlations were observed between improvements in PROs and DAS28 (data not 
shown). ConClusions: Improvements observed to Wk24 in generic and disease-
specific PROs were sustained to Wk96 of the RAPID-PsA trial for both CZP dosing 
regimens.
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objeCtives: Pain medication diaries have traditionally been collected via paper 
due to challenges of patients entering unlimited medications, units, dosages, and 
administration schedules. This study developed an electronic diary that permits site 
staff to enter medications that patients are taking, enables the patient to update 
medication taken and to enter new medications within the reporting period, and 
reduces the possibility of cheating behaviors during the study. Usability of this 
electronic diary was evaluated to ensure that patients in a clinical trial setting could 
successfully update their diaries in real-time to accurately track pain medication 
intake. Methods: A cross-sectional qualitative study was conducted involving 
usability interviews with patients diagnosed with osteoarthritis of the hip or knee 
who were taking pain medication. Interviews were conducted in two waves of 10 
participants each, allowing for evaluation of findings and revisions to the eDiary 
between waves. Results: Mean age of the sample (N= 20) was 66 years (range 
43-78), 90% over 60 years old; 60% were female; 95% were white; 70% completed 
secondary school or some college. In wave 1, issues were noted with training, select-
ing responses, exiting to send data, and some wording. For wave 2, the training 
module was revised to more closely match the diary, wording was revised, and a 
screen added to facilitate exiting the diary. No issues were noted with training, 4 
had trouble selecting responses, and 3 suggested additional instructions on the 
new screen. No additional changes were made following wave 2. ConClusions: 
The study showed it is possible to develop an electronic pain medication diary 
that allows patients to update their medications during a study. Extensive training 
was critical to the usability of the electronic version. The two wave study design 
provided the opportunity to detect and make changes to the eDiary with marked 
improvement in wave 2.
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objeCtives: Spondyloarthritis (SpA) is a group of diseases that share common clini-
cal, radiographic and genetic features. Axial SpA is one major subgroup including 
patients with radiographic (rad-axSpA) and non-radiographic axSpA (nr-axSpA). 
There has been limited research on axSpA patients in clinical practice and the 
impact of the disease on patient’s health-related quality of life (HrQoL). The aim 
of this study was to characterize patients with axSpA in clinical practice and to 
investigate similarities/differences between rad-axSpA and nr-axSpA with respect 
to their HrQoL. Methods: This is a longitudinal, multi-center cohort study where 
patients were consecutively recruited from Swedish clinical practice and followed 
for 3 months. At baseline, the rheumatologists registered information on disease 
history, extra articular manifestations and treatments. The patients answered 
online questionnaires capturing patient demographics, disease activity, function 
and HrQoL. HrQoL was measured using the EQ-5D and the Ankylosing Spondylitis 
Quality of Life Questionnaire (ASQoL). While higher scores in the EQ-5D indicate bet-
ter HrQoL, the opposite is true for the ASQoL. Results: 251 patients were included 
of whom 197 (78%) were classified as axial SpA. Of those, 125 (63%) were classi-
fied as rad-axSpA and 72 (37%) as nr-axSpA according to the ASAS axSpA criteria. 
There were more women in the nr-axSpA group (50%) compared with the rad-axSpA 
group (38%). The nr-axSpA patients had a shorter time between symptom onset and 
diagnosis than the rad-axSpA patients (6.7 vs. 9.0 years) and a significantly higher 
disease activity (BASDAI= 4.1 vs 2.7, p< 0.001). Mean EQ-5D score at baseline was 
0.66 for rad-axSpA and 0.61 for nr-axSpA, lower than the Swedish general popula-
tion (0.84). ASQoL scores was significantly higher in the nr-axSpA group (8.8 vs 6.4, 
p= 0.016). ConClusions: HRQoL is poorer in axial SpA patients compared to the 
general population and patients with nr-axSpA reported a higher impact on HRQoL 
than patients with rad-axSpA.
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objeCtives: Rheumatic diseases (RD) have been associated with functional and 
work-related disability due to the deliberating and progressive nature of these 
diseases and have many deleterious consequences on patients’ life. The aim of the 
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objeCtives: Despite widespread treatments for Osteoarthritis (OA), data on 
treatment patterns, adequacy of pain relief, and quality of life are limited. The 
prospective multinational Survey of Osteoarthritis Real World Therapies (SORT) 
was designed to investigate these aspects. This analysis aims to describe the clini-
cal characteristics and the patient reported outcomes of the Portuguese dataset 
of SORT baseline. Methods: The statistical analysis included, from January to 
December of 2011, 192 participants ≥ 50 years or older with primary knee OA 
from 7 health care centers in Portugal who were receiving oral or topic analgesics. 
Inadequate Pain Relief (IPR) was defined as a score > 4/10 in item 5 of the Brief Pain 
Inventory (BPI), indicating moderate to severe pain. Results: Overall, the median 
age was 67.0 ± 8.7 years and 77.6% were female. Mean duration of knee OA was 
6.3 ± 6.3 years. IPR was reported by 52.0% of the patients. The most prescribed 
analgesics were NSAIDs (88.1%), alternative therapies, including glucosamine, 
chondroitin and hyaluronate (44.3%) and paracetamol (28.6%). Patients with IPR 
scored higher than non-IPR patients in WOMAC – Stiffness (61.0 vs 39.7, p< 0.001) 
and WOMAC – physical function (59.2 vs 39.4, p< 0.001), meaning worse condi-
tion. Patients with IPR had worse quality of life related to knee osteoarthritis as 
measured by the SF-12 questionnaire (fair/poor: 86.9% vs. 72.0%, p< 0.001). 62.0% 
of patients with IPR were dissatisfied or very dissatisfied with the effects of anal-
gesics versus 34.0% of patients with non-IPR (p< 0.05). ConClusions: Despite the 
use of analgesics, over half of the Portuguese patients in SORT reported moderate 
to severe knee pain. Worse outcomes were also observed in this group regarding 
other symptoms of knee OA and general quality of life. These findings suggest 
that if an improvement of pain management in knee OA can be achieved, it may 
have high impact on patients’ lives.
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objeCtives: Prior equivalence work with the WOMAC® scale was published for 
the VAS scale and older touchscreen computer technology. Additional equivalence 
evaluation of the WOMAC®NRS3.1 and the Patient Global Assessment (PGA) in a 
newer tablet with stylus was needed to document suitability of this mode of data 
collection for these instruments in upcoming clinical trials. Methods: A cross-sec-
tional qualitative study was conducted involving cognitive and usability interviews 
with patients diagnosed with osteoarthritis of the hip or knee who were taking 
pain medication for their condition. Interviews were conducted in two waves of 10 
participants each, with revisions to the PGA made in between the rounds, which 
allowed for changes to the electronic version to be evaluated. Results: Mean age 
of the sample (N= 20) was 66 years, (range 43-78), 90% over 60 years old; 60% were 
female; 95% were white; 75% were retired; 70% had completed secondary school or 
some college, while 30% had completed college or a post-graduate degree. In wave 
1, minor issues were found with completing the WOMAC®, mainly with using the 
stylus to select responses and glare on the screen. There were no issues identified 
in interpreting the response scale. For the PGA, 50% (5/10) used the wrong recall 
period (48 hours or longer). The PGA recall period was revised from “at this time” 
to “over the past 24 hours” and bolded for emphasis. In wave 2, similar issues with 
glare and stylus response were found, while 80% used the correct recall period on 
the PGA, with 20% using 48 hours. ConClusions: The study showed excellent 
qualitative equivalence between the paper and electronic WOMAC® with only minor 
usability issues. The two wave study design provided the opportunity to detect and 
make changes to the PGA recall period and formatting that showed improvement 
in the second wave.
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objeCtives: To report the effect of certolizumab pegol (CZP), a PEGylated Fc-free 
anti-TNF, on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) over 96 
weeks (wks) of the RAPID-PsA trial. Methods: The RAPID-PsA trial (NCT01087788) 
is double-blind and placebo-controlled to Wk24, dose-blind to Wk48 and open-label 
to Wk216. Patients had active PsA and had failed ≥ 1 DMARD. Patients originally ran-
domized to CZP (200mg Q2W or 400mg Q4W, following 400mg loading dose at Wk0, 
Wk2, Wk4) continued on their assigned dose in the dose-blind phase and OLE. Here 
we present PRO data for the CZP-treated randomized set, including mean change 
from baseline (CFB) and Minimal Clinically Important Differences (MCIDs). Data 
were also analysed for CZP-randomized patients with (19.8%) or without (80.2%) 
prior anti-TNF exposure. Missing data were imputed by LOCF. Correlations between 
clinical outcomes and PROs were also investigated. Results: Of 273 patients 
